%0 Journal Article
%T IL-6/STAT3信号通路在非小细胞肺癌发生和治疗中的进展<br>Progress of IL-6/STAT3 Signaling Pathway in the Development and Treatment of Non-Small Cell Lung Cancer
%A 唐玉平
%A 沈存芳
%J Advances in Clinical Medicine
%P 9953-9960
%@ 2161-8720
%D 2022
%I Hans Publishing
%R 10.12677/ACM.2022.12111435
%X IL-6/STAT3通路是非小细胞肺癌发展的关键途径之一，可通过参与癌细胞的抗凋亡、增殖及肿瘤血管生成等多种恶性表型促进肿瘤发展。此外，临床研究表明，IL-6/STAT3信号通路与非小细胞肺癌的化疗、靶向及放疗耐药相关，针对IL-6/STAT3信号通路的靶向药物对非小细胞肺癌的治疗有益，有望成为治疗非小细胞肺癌的有效药物。深入了解IL-6/STAT3信号通路与非小细胞肺癌的关系有助于阐明非小细胞肺癌发病机制，并为其治疗提供新方向。本文就该通路在非小细胞肺癌发展及治疗中的最新进展作一综述。<br />
The IL‐6/STAT3 pathway is one of the key pathways in the development of non-small cell lung can-cer (NSCLC), which can promote the development of tumor by participating in various malignant phenotypes such as anti-apoptosis, proliferation and tumor angiogenesis. In addition, clinical stud-ies have shown that IL‐6/STAT3 signaling pathway is associated with chemotherapy, targeting and radiotherapy resistance of NSCLC. Targeted drugs targeting IL‐6/STAT3 signaling pathway are ben-eficial for the treatment of NSCLC and are expected to be effective drugs for the treatment of NSCLC. A deeper understanding of the relationship between IL-6/STAT3 signaling pathway and NSCLC will help clarify the pathogenesis of NSCLC and provide a new direction for its treatment. This article re-views the latest progress of this pathway in the development and treatment of non-small cell lung cancer.
%K 恶性肿瘤，非小细胞肺癌，白介素-6，IL-6/STAT3信号通路<br>Malignant Tumor
%K Non-Small Cell Lung Cancer
%K IL-6
%K IL-6/STAT3 Signaling Pathway
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=57584